Search

Displaying results 2161 - 2170 of 3388 in total
  1. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  2. Drug

    Azasetron

    go.drugbank.com/drugs/DB16837
    Investigational

    Categories: P-glycoprotein substrates, Serotonin Receptor Antagonists
  3. Drug

    Naringin

    go.drugbank.com/drugs/DB16859
    Experimental

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.

    Categories: Corticotropin-releasing Factor Type 1 Receptor Antagonist, Cytochrome P-450 Substrates
  5. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    Benzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  6. Drug

    Hydrastine

    go.drugbank.com/drugs/DB19354
    Experimental

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Equilenin

    go.drugbank.com/drugs/DB03515
    Experimental

    Equilenin is an estrogenic steroid produced by horses. It has a total of five double bonds in the A- and B-ring. High concentration of equilenin is found in the urine of pregnant mares.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transport...

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  9. Drug

    Ribostamycin

    go.drugbank.com/drugs/DB03615
    ApprovedWithdrawn

    Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.

  10. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates